Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.46 |
| ▸ | PPARA | Q07869 | 9/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26499313 | 0.91 | PPARD (0.45) | PPARDPPARAPPARGMAPTRAB9A | |
| SCHEMBL26499297 | 0.84 | MAPT (0.47) | PPARDPPARAPPARGMAPTRAB9A | |
| SCHEMBL29124529 | 0.84 | PPARD (0.44) | PPARDPPARAPPARGMAPTRAB9A | |
| SCHEMBL13499289 | 0.84 | PPARD (0.46) | PPARDPPARAPPARGRAB9AROCK2 | |
| SCHEMBL22349797 | 0.81 | PPARD (0.48) | PPARDPPARAPPARGMAPTRAB9A | |
| SCHEMBL26499306 | 0.79 | DRD2 (0.51) | PPARDPPARAPPARGALDH1A1TDP1 | |
| SCHEMBL17188123 | 0.78 | MYC (0.44) | PPARDPPARAPPARGDGAT1 | |
| SCHEMBL26499303 | 0.77 | ALDH1A1 (0.46) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL27596024 | 0.77 | DGAT1 (0.45) | PPARDPPARAPPARGMAPTRAB9A | |
| SCHEMBL26499309 | 0.76 | KCNH2 (0.47) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321082-A1 | USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS | RABL3, VAPA, VAPB | PPARD 1920/4885PPARA 2605/4885PPARG 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.